TITLE

A Targeted Approach for Antiangiogenic Therapy of Metastatic Human Colon Cancer

AUTHOR(S)
Ellis, Lee M.
PUB. DATE
January 2003
SOURCE
American Surgeon;Jan2003, Vol. 69 Issue 1, p3
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The realization that the growth and spread of tumors are dependent on angiogenesis has created new avenues of research designed to help us to better understand cancer biology and to facilitate the development of new therapeutic strategies. However, the process of angiogenesis consists of multiple sequential and interdependent steps with a myriad of positive and negative regulators of angiogenesis being involved. The survival of tumors and thus their metastases are dependent on the balance of endogenous angiogenic and antiangiogenic factors such that the outcome favors increased angiogenesis. Several growth factors have been identified that regulate angiogenesis in colon cancer; the most important of these is vascular endothelial growth factor. In addition, specific integrins such as α[sub v]β[sub 3] and α[sub 5]β[sub 1] mediate endothelial cell survival and have been shown to be overexpressed on the endothelium of colon cancer. These angiogenic mediators thus serve as targets for therapy of metastatic colon cancer and have shown promise in preclinical trials.
ACCESSION #
10544869

 

Related Articles

  • Anti-angiogenic therapy and radioimmunotherapy in colon cancer xenografts. Kinuya, Seigo; Kawashima, Atsuhiro; Yokoyama, Kunihiko; Kudo, Miho; Kasahara, Yoshihito; Watanabe, Naoto; Shuke, Noriyuki; Bunko, Hisashi; Michigishi, Takatoshi; Tonami, Norihisa // European Journal of Nuclear Medicine;2001, Vol. 28 Issue 9, p1306 

    Angiogenesis is critical to the growth and metastatic process of malignant tumors. An endogenous estrogen metabolite, 2-methoxyestradiol (2-ME), displays anti-angiogenic and anti-tumorigenic effects. The purpose of this investigation was to determine whether exogenously administered 2-ME would...

  • Role of cyclooxygenase-2 in the angiogenesis of colorectal cancer. Rao, Milind; Wenxuan Yang; Seifalian, Alexander M.; Winslet, Marc C. // International Journal of Colorectal Disease;Jan2004, Vol. 19 Issue 1, p1 

    Background. Cyclooxygenase (COX) is the rate-limiting enzyme in the synthesis of prostaglandins. It exists in two isoforms: COX-1 which is constitutively expressed and COX-2 which is an inducible form activated by a variety of cytokines during inflammation. Discussion. Interest in this enzyme...

  • Molecular Pathways Underlying IBD-Associated Colorectal Neoplasia: Therapeutic Implications. Goel, Gati A.; Kandiel, Ahmed; Achkar, Jean Paul; Lashner, Bret // American Journal of Gastroenterology;Apr2011, Vol. 106 Issue 4, p719 

    Chronic inflammatory diseases, depending upon the duration and severity, are frequently associated with an increased risk of developing cancer. A classic paradigm is the enhanced risk of colorectal cancer (CRC) in patients with inflammatory bowel disease (IBD). Carcinogenesis is a multifactorial...

  • Bevacizumab. Ellis, Lee M.; Kirkpatrick, Peter // Nature Reviews Drug Discovery;May2005 Supplement, Vol. 4, pS8 

    Bevacizumab (Avastin; Genentech/Roche), an antibody against vascular endothelial growth factor, was approved by the US FDA in February 2004 for the first-line treatment of metastatic colorectal cancer in combination with 5-fluorouracil-based chemotherapy. It is the first approved agent to target...

  • Antiangiogenesis Research Is Booming, As Questions and Studies Proliferate. Brower, Vicki // JNCI: Journal of the National Cancer Institute;6/2/2009, Vol. 101 Issue 11, p780 

    The article focuses on the issues embedded in the approval of the U.S. Food and Drug Administration on bevacizumab as an inhibitor of angiogenesis for patients with progressed colorectal cancer. The author comments that there is an increase in the number of angiogenesis inhibitors (AI) research,...

  • Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy. Paré-Brunet, L; Sebio, A; Salazar, J; Berenguer-Llergo, A; Río, E; Barnadas, A; Baiget, M; Páez, D // Pharmacogenomics Journal;Oct2015, Vol. 15 Issue 5, p397 

    Angiogenesis is a significant biological mechanism in the progression and metastasis of solid tumors. Vascular endothelial growth factor (VEGF), its receptors and signaling effectors have a central role in tumor-induced angiogenesis. Genetic variation in the VEGF pathway may impact on tumor...

  • Regorafenib.  // Australian Prescriber;Jun2014, Vol. 37 Issue 3, p103 

    The article offers information on the Regorafenib, a drug for treating patients with metastatic colorectal cancer. It states that it is a protein kinase inhibitor with similar structure to sorafenib and is believed to work by inhibiting multiple signaling pathways involved with angiogenesis and...

  • The in vitro Effects of a Tomato Extract on Neoangiogenesis-Controlling Molecules in Colon Carcinoma Cells. Cenariu, Diana; Fischer-Fodor, Eva; Virag, Piroska; Tatomir, Corina; Pintea, Adela; Cenariu, Mihai; Mocan, Andrei; Crişan, Gianina // Scientific Papers: Animal Science & Biotechnologies / Lucrari St;2015, Vol. 48 Issue 1, p112 

    The aim of this study was to reveal the antiproliferative effect of two tomato extracts on colorectal cancer cells in vitro, and to show their influence on the secretion of growth factors involved in tumor neoangiogenesis: VEGF and Endothelin-1, in order to reveal some of the inhibitory...

  • basic science.  // Annals of Oncology;2016 Supplement, Vol. 27, pvi1 

    No abstract available.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics